Investigating the interaction pattern of FDA approved compounds with <i>Mycobacterium tuberculosis</i> GidB to understand their potential as antibiotics

and proposes the mentioned drugs as promising inhibitors of GidB for future pre-clinical investigations. Through this multi-step structure-based drug repurposing workflow 4 promising inhibitors of GidB were identified. The identified compounds offer a promising avenue for developing new anti-TB drugs, potentially bolstering the arsenal against drug-resistant strains. Their discovery represents hope for those fighting against the relentless spread of tuberculosis, bringing us closer to more effective treatments for patients in need.